Summit Financial, LLC Esperion Therapeutics, Inc. Transaction History
Summit Financial, LLC
- $6 Billion
- Q3 2025
A detailed history of Summit Financial, LLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Summit Financial, LLC holds 98,638 shares of ESPR stock, worth $286,050. This represents 0.0% of its overall portfolio holdings.
Number of Shares
98,638
Previous 74,785
31.9%
Holding current value
$286,050
Previous $73,000
257.53%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ESPR
# of Institutions
214Shares Held
114MCall Options Held
643KPut Options Held
769K-
Black Rock Inc. New York, NY14MShares$40.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.1MShares$35.1 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY9.75MShares$28.3 Million0.51% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT7.06MShares$20.5 Million0.1% of portfolio
-
Pender Fund Capital Management Ltd. Vancouver, A16.68MShares$19.4 Million7.68% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $193M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...